Telomir Pharmaceuticals has taken a significant step forward in the development of a novel therapeutic agent for one of oncology’s most challenging cancers. As reported by Pharmaceutical Technology, the company has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration for Telomir-1 (Telomir-Zn), a groundbreaking candidate designed to address advanced and metastatic triple-negative breast cancer (TNBC).
This IND submission represents a major milestone, incorporating comprehensive data from completed toxicology, pharmacology, and manufacturing studies, all essential components for regulatory evaluation. Upon FDA clearance, Telomir Pharmaceuticals plans to initiate a Phase I/II clinical trial, with Telomir-1 administered as an oral single agent to patients with advanced or metastatic disease.
A Novel Mechanism of Action
Telomir-Zn distinguishes itself as a first-in-class metal-modulating epigenetic agent, specifically engineered to restore transcriptional control in tumor cells. This innovative approach targets iron-dependent epigenetic dysregulation, a biological mechanism that drives treatment resistance in TNBC patients, representing a scientifically differentiated therapeutic strategy.
Encouraging Preclinical Results
The supportive safety studies conducted under good laboratory practice (GLP) standards demonstrated no treatment-related or dose-limiting toxicities. The agent exhibited favorable cardiovascular, respiratory, and phototoxicity profiles, while maintaining consistent systemic exposure and predictable pharmacokinetics—critical factors that bode well for clinical translation.
Rigorous Clinical Trial Design
The upcoming Phase I component will employ a standard three-plus-three dose-escalation design to evaluate safety, tolerability, and dose-limiting toxicities while establishing the recommended Phase II dose. The subsequent Phase II phase will utilize a Simon two-stage design to assess preliminary anti-tumor activity, with the objective response rate as the primary endpoint, alongside evaluation of duration of response and progression-free survival.
Path Forward
Telomir Pharmaceuticals plans to disseminate findings through peer-reviewed publications and presentations at prominent scientific conferences, including the American Association for Cancer Research annual meeting scheduled for 2026. This commitment to scientific transparency underscores the company’s dedication to advancing treatment options for TNBC patients who currently have limited durable therapeutic alternatives.
